Senti Bio to Present at BioJapan
In-person presentation on Thursday, October 9th at 11:30 AM JST
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at BioJapan being held October 8-10, 2025 in Yokohama, Japan.
Details of the presentation are as follows:
Presenter: Timothy Lu, MD, PhD, CEO and Co-Founder of Senti Biosciences
Date and Time: Thursday, October 9th at 11:30 AM JST
Location: Presentation Stage C, PACIFICO Yokohama Convention Center, Yokohama, Japan
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference, and will have a booth (D-53) in the exhibition hall.
For more information, please visit the conference website.
About BioJapan
BioJapan is Asia's premier bio-industry partnering event, comprising an Exhibition, Seminars, and Partnering sessions. As the world’s longest-running biotech exhibition, BioJapan, along with its two co-located events—Regenerative Medicine Japan, which accelerates R&D and commercialization in regenerative medicine, and healthTECH Japan, focusing on health management, diagnostics, and therapeutics through the integration of digital technology and life sciences— continues to drive innovation and collaboration in the industry.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
